The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Germ cell tumor (GCT) is one of the most common malignancies affecting young men. Approximately 30% of patients with metastatic disease experience disease progression following adequate first-line ...

Binod Dhakal, MD, associate professor, division of hematology and oncology, Medical College of Wisconsin and lead investigator of the CARTITUDE-4 study, presented updated data at the 2024 ...

Evaluating the correlation between clonal hematopoiesis and response to regorafenib and nivolumab in patients with refractory metastatic colorectal cancer. KEYSTEP-008: Pembrolizumab (pembro)-based ...

Incyte (NYSE: INCY) today announced that MINJUVI® (tafasitamab) in the treatment of relapsed or refractory follicular lymphoma (R/R FL) has been funded in the province of Ontario through Ontario's ...

Teclistamab-cqyv significantly improves progression-free and overall survival in relapsed/refractory multiple myeloma, especially in patients refractory to anti-CD38 therapy and lenalidomide. The ...

CHMP recommendation follows positive Phase 3 study results, marking the second Phase 3 study to demonstrate benefit with a TECVAYLI®-based regimen in the second-line setting1,2Results demonstrated ...

Refractory metastatic colorectal cancer remains a major clinical challenge, with limited efficacy of conventional cytotoxic regimens in patients who have progressed beyond standard lines of therapy.

DENALI-1 is a first-in-human, open-label, Phase 1/2 study evaluating the safety and recommended Phase 2 dose of A2B395 in adults with previously treated EGFR-positive advanced solid tumors. DENALI-1 ...